Cardiac rehab for heart amyloidosis
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests a 5-week cardiac rehabilitation program for people with cardiac amyloidosis (a condition where abnormal protein builds up in the heart). The program aims to improve heart function and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of cardiac amyloidosis called ATTR, confirmed by a special heart scan.
- You are able to do a stress test (exercise test) safely.
- You can start the 5-week rehab program within 30 days of the stress test.
- You do not have uncontrolled irregular heartbeats or severe heart failure (NYHA Class IV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This study uses a new type of heart scan (MCG) to help understand cardiac amyloidosis. It may help doctors learn more about the condition without needing invasive tests.
This study tests whether a 12-week supervised exercise program is safe and helpful for people with cardiac amyloidosis and heart failure. It aims to see if regular exercise can improve how you feel and function.
This study tests a personalized exercise program for people with cardiac amyloidosis to see how it affects their heart and daily life. The goal is to help you feel better and stay active safely.
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
This trial studies whether ultrasound therapy can help people with amyloidosis that affects the heart. It’s aimed at improving heart-related outcomes in AL or transthyretin (ATTR) cardiac amyloidosis.
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.